61 results
8-K/A
EX-99.3
CRVO
CervoMed Inc
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
is directly linked with the initiation of the neurodegenerative process through synaptic dysfunction. Our technology targets the molecular mechanisms within … University Langone Medical Center, we have demonstrated that neflamapimod specifically targets the specific molecular mechanisms underlying basal forebrain
424B3
CRVO
CervoMed Inc
13 Jul 23
Prospectus supplement
4:32pm
to TSC and had the potential to diversify and reduce the perceived risk profile of Diffusion’s asset portfolio as targets for an acquisition
S-4/A
dcsbaepiju505 wv
22 Jun 23
Registration of securities issued in business combination transactions (amended)
9:46pm
S-4
kyez8la1f0av 40w
10 May 23
Registration of securities issued in business combination transactions
9:56pm
424B3
s6z9n
8 Jun 20
Prospectus supplement
4:48pm
424B5
4fc6gb03x5pxliulr5ih
19 May 20
Prospectus supplement for primary offering
5:29pm
424B3
i1roit 2cfoo
30 Dec 19
Prospectus supplement
10:07am
424B5
5swwgecu
13 Dec 19
Prospectus supplement for primary offering
7:59am
424B4
rlig8dwhh d6pizgig
15 Nov 19
Prospectus supplement with pricing info
12:00am